Pantethine, an active form of vitamin B5, is a gentle, well-tolerated way to nudge blood fats in a healthier direction — lowering triglycerides most, with smaller drops in bad cholesterol. Effects are larger when starting levels are high and small when near optimal, and it spares the energy nutrient that cholesterol drugs deplete. (Full Review)

Protocol

Dose

600–900 mg/day

Start 300–600 mg, titrate up over 1–2 weeks

Schedule

Split doses, with meals

300 mg two to three times daily

Form

Sustained-release (Pantesin)

Reference formulation used in most trials

Time to effect

Triglycerides

A few weeks

Earliest, most responsive marker

Cholesterol

8–16 weeks

Full effect on LDL and total cholesterol

Follow-up panel

2–4 months

Deferred until effect is near maximal

Benefits

Medium: Triglyceride reduction; LDL and total cholesterol reduction

Low: HDL cholesterol increase; lipid improvement in diabetic and kidney-disease dyslipidemia; lipid lowering without CoQ10 depletion

Speculative: Neuroprotection and cognitive support; immune and anti-inflammatory modulation; antitumor immunity support

Contraindications

Pregnancy or breastfeeding

Hypersensitivity to pantethine or cysteamine-type sulfur compounds

Key Interactions

Statins (atorvastatin, rosuvastatin, simvastatin)

Fibrates and niacin (fenofibrate, gemfibrozil)

Lipid-lowering supplements (red yeast rice, plant sterols, berberine, omega-3, artichoke leaf)

Anticoagulants and antiplatelet agents (aspirin, clopidogrel, warfarin, high-dose fish oil)

Risk & Side Effects

Medium: Gastrointestinal discomfort

Low: Additive bleeding risk from reduced platelet aggregation; allergic reaction or hypersensitivity

Speculative: Unknown long-term safety at higher doses; uncertain safety in pregnancy and lactation

Monitoring

Marker	Target	Why
Triglycerides	< 80 mg/dL	Primary target most responsive to pantethine
LDL cholesterol	< 100 mg/dL	Main cholesterol target; tracks the modest LDL effect
Total cholesterol	< 180 mg/dL	Overall lipid burden; falls with LDL
HDL cholesterol	> 55 mg/dL (men), > 60 mg/dL (women)	Detects any favorable HDL change
Apolipoprotein B (apoB)	< 90 mg/dL	Particle-count measure of atherogenic risk
Fasting glucose / HbA1c	Glucose 75–90 mg/dL; HbA1c < 5.4%	Confirms no adverse effect on blood sugar
ALT / AST	< 25 U/L	Baseline organ safety, especially with combined lipid drugs

Cadence: Lipid panel at 8–12 weeks, then every 6–12 months; add liver and kidney checks periodically if combined with prescription lipid drugs

Qualitative Assessment

Absence of new gastrointestinal symptoms (nausea, loose stools, heartburn) as a tolerability signal
General energy and sense of wellbeing, consistent with its role in fat-based energy metabolism
No easy bruising or unusual bleeding, particularly if combined with anticoagulants

Pantethine for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment